Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

A Phase II Trial of Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field RT improves 2-year PFS in those patients than that of historical data (only with other standard salvage treatments as systemic chemotherapy ± maximum tumor resection).

Inclusion Criteria:

• Pathologically confirmed ovarian carcinoma
• Patients who received "standard treatment" for each stage as a primary treatment
• No. of recurrent lesions:

If, all in lung, or intra-abdominal or pelvis organs - ≤ 5 If, any in liver, bone, or spinal cord - ≤ 2

• Size of recurrent lesions ≤5 cm
• All recurrent lesions are available for involved-field radiotherapy
• Within 60 days before enrollment:
• Absolute neutrophil count ANC ≥ 500 / mm3
• Platelet ≥ 50,000 / mm3
• Hb ≥ 8.0 g / dl
• Good performance status (ECOG 0-1)

Exclusion Criteria:

• Brain metastasis
• Diffuse peritoneal carcinomatosis
• Malignant pleural effusion
• History of previous salvage radiotherapy for recurrent lesions
• History of other malignancy or severe/unstable medical condition